Background Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that
targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of …

Background Preclinical data have suggested that nintedanib, an intracellular inhibitor of
tyrosine kinases, inhibits processes involved in the progression of lung fibrosis. Although the …

Acute exacerbation of idiopathic pulmonary fibrosis has been defined as an acute, clinically
significant, respiratory deterioration of unidentifiable cause. The objective of this …

Different animal models of pulmonary fibrosis have been developed to investigate potential
therapies for idiopathic pulmonary fibrosis (IPF). The most common is the bleomycin model …

IL-1β is one of a family of proinflammatory cytokines thought to be involved in many acute
and chronic diseases. Although it is considered to participate in wound repair, no major role …

Idiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal disease characterised
by fibrosis of the lung parenchyma and loss of lung function. Although the pathogenic …

Rationale: The clinical management of idiopathic pulmonary fibrosis (IPF) remains a major
challenge due to lack of effective drug therapy or accurate indicators for disease progression. …

The views and recommendations made in this document do not represent the official position
of any publisher or professional medical society. This document has not been endorsed by …

Transforming growth factor-β1 plays a key role in the pathogenesis of pulmonary fibrosis,
mediating extracellular matrix (ECM) gene expression through a series of intracellular …

Background The INBUILD trial investigated the efficacy and safety of nintedanib versus
placebo in patients with progressive fibrosing interstitial lung diseases (ILDs) other than …